[Lymphatic invasion of the bladder wall in T1 superficial bladder carcinoma. Prognostic value].
BACKGROUND
It is not usual to use as prognostic factor the bladder lymphatic vessels invasion.


METHODS
519 T1 bladder tumors with complete resection and follow up of one year at least. Prophylaxis with 81 mg of BCG weekly during six weeks in 54%.


RESULTS
Follow up without recurrence of 38 months. 49%. Tumour recurrence of 49% and progression of 7%. 5.8% of the tumours are L1 and 70.7% L0. There are significative statistic relation between lympatic invasion and progression (p. 005), tumoral grade (p. 000) and actual situation (p. 02). 23% of the L1 tumours progressed vs 5% of L0. Prophylaxis with BCG reduces progression risk (33% without treatment vs 16 with BCG (p n.s.)). In multivariate analysis, resected volume (p. 024) and prophylactic treatment are independent variables for recurrence and lymphatic vessels invasion (p. 0478) and tumoral grade (p. 092) for progression.


CONCLUSIONS
1) L1 tumours has more probabilities of progression. 2) BCG disminishes progression rate but this is not statistical significative. 3) We need new markers to select which L1 tumours will progress.
Moyano Calvo
J L
JL
Cátedra y Servicio de Urología, Hospital Universitario Virgen Macarena, Fundación Joaquín Albarrán, Sevilla.
Ortiz Gámiz
A
A
Poyato Galán
J M
JM
Gutiérrez González
M
M
Sánchez Sánchez
E
E
Alvarez-Ossorio Fernández
J L
JL
Castiñeiras Fernández
J
J
D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015653:Cystectomy; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000473:pathology; D011379:Prognosis; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy
D001500:BCG Vaccine